Fig. 1

Neoadjuvant cancer immunotherapy trials and translational companion studies like Rahim et al. provide unique opportunities to guide the development and benchmarking of pre-clinical models to reiterate knowledge and improve the clinical trial design. Figure created with BioRender.com